KMTS Stock Forecast & Price Target

Kestra Medical Techs is attractive because it is delivering rapid commercial traction, with F1Q27 sales of $31.0M, up 60% y/y, and FY27 revenue guidance raised to $141M, supported by market share gains, new account activations, and deeper penetration of existing accounts. Its fundamentals are also strengthening as gross margin expanded to 56.5% in F1Q27 from 45.7% a year earlier, marking the 11th consecutive quarter of sequential improvement, while total liquidity of about $320M provides ample runway for continued investment. The outlook is further reinforced by the ASSURE WCD’s strong clinical profile, broad payor coverage, and scaling salesforce, which together support expectations for continued beat-and-raise execution and longer-term margin expansion.

Kestra Medical Techs is facing a weak fundamental outlook because the WCD market itself remains burdened by subjective patient selection, heterogeneous prescribing, and uncertain mortality benefit, making broad adoption hard to justify. The company’s ASSURE platform may improve electrode contact and wear time, but the core business still depends on patients wearing the device >22 hours per day, while noise events, false alarms, discomfort, and skin-related issues continue to undermine adherence and outcomes. The benchmark VEST trial in 2,348 patients failed to meet its primary endpoint, with arrhythmic death of 1.6% versus 2.4% and median wear time of only 18.0 hours/day, reinforcing doubts about real-world effectiveness and cost-effectiveness.